Korro Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $154.5M
- Price
- $10.49
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.48%
- Volume
- 157.0K
About
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Quick stats
Shares outstanding14.7M
Computed float11.7M
Float / shares79.4%
Cash runway (months)17.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001703647
Websitehttps://www.korrobio.com
AI Summary
AI-generated1/21
standardbullishclinical trial
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
Korro Bio dosed the first cohort of healthy volunteers in its Phase 1/2 ANCHOR trial of KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia in urea cycle disorders and hepatic encephalopathy.
The first cohort received a single 2mg/kg dose; the trial is enrolling in Australia with Part 1 (SAD/MAD) in up to 50 healthy volunteers and Part 2 in up to 15 UCD patients across all genotypes.
Dosing of UCD patients is expected in the first half of 2027 with an interim readout in the second half of 2027, making this an early safety-stage milestone rather than a near-term catalyst.
Red flags
- patient data not expected until H2 2027 interim readout